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Abstract The aim of this study was to evaluate protein
expression of Karyopherin alpha 2 (KPNA2) in invasive
breast cancer and matched ductal carcinoma in situ (DCIS)
and to correlate it with clinicopathological data, including
patient survival. KPNA2 protein expression was assessed
by immunohistochemistry in breast tissue samples, con-
taining invasive carcinomas, DCIS, and adjacent histolog-
ically benign breast tissues. A polyclonal goat KPNA2
antibody was used for immunostaining of 83 clinicopath-
ologically characterized cases. For statistical analysis,
staining of at least 10% of nuclei was considered KPNA2
positive. Immunohistochemical detection of KPNA2 in
invasive carcinoma showed a significant correlation with
higher tumor stage, positive lymph node status, higher
tumor grade, and negative ER status. Concordantly,
KPNA2-positive tumors (31.3%) showed significantly shorter
disease-free survival times (69 months vs 118 months; p=
0.007). KPNA2 protein expression was also detected in
DCIS (21.3%) adjacent to invasive tumor and correlated with
nuclear grade (p=0.013). Expression of KPNA2 in invasive
breast cancer correlates with conventional prognostic param-
eters and shorter disease-free survival. Additionally, KPNA2
is overexpressed in DCIS, particularly high grade lesions,
which emphasizes its potential role in carcinogenesis of
invasive breast carcinomas.
Keywords Breast cancer . DCIS . KPNA2 .
Prognostic marker . Immunohistochemistry
Introduction
Breast cancer is the most common malignant neoplasm of
women in the Western world, with an estimated number of
178,480 new cases of breast cancer among US women in
2007 [4]. Recent diagnostic and therapeutic advances are
encouraging, but at the same time, increasingly detailed
prognostic information is required, which should exceed
conventional prognostic parameters, i.e., age, nodal status,
tumor size, tumor grade, tumor type, and receptor status.
This condition seems to be met by several promising
molecular markers like Kallikrein 5 [20], urokinase plas-
minogen activator and its inhibitor [9], tissue inhibitor of
metalloproteinase 1 [10], Ep-CAM [17], osteopontin [12],
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CD24 [8], SFRP1 [7], survivin [13, 16], and Karyopherin
alpha 2 (KPNA2) [2, 15, 19].
Several gene expression profiling studies demonstrated
overexpression of KPNA2, a member of the karyopherin
alpha protein family, in breast cancer tissue [2, 15, 19].
Proteins of the karyopherin alpha family play a central role
in nucleocytoplasmic transport. They act as an adaptor in the
nuclear import of macromolecules by binding cargoproteins,
which contain a classical nuclear localization signal, thereby
linking them to the transport protein karyopherin beta. A
strong nuclear KPNA2 immunoreactivity was observed in
breast cancer cells compared to a weak or absent staining in
normal breast tissue by Dahl et al. [2]. They also
demonstrated an independent negative correlation between
nuclear KPNA2 protein expression in the primary tumor
and overall survival of breast cancer patients.
So far, no data on KPNA2 protein expression in
preinvasive lesions of the breast are available. We,
therefore, aimed to investigate the expression of KPNA2
immunohistochemically in a cohort of clinically character-
ized breast cancer samples and matched peritumoral ductal
carcinoma in situ (DCIS) to verify the prognostic properties
in invasive cancer and to focus on KPNA2 expression in
adjacent DCIS.
Materials and methods
Patients
The study included 83 patients with breast cancer, diagnosed
at the Institute of Pathology, University Hospital Charité,
Berlin, between 1991 and 1997. Patient age at the time of
diagnosis ranged from 30 to 80 with a mean of 58 years.
Clinical follow-up data, including overall survival and
disease-free survival, were available for all cases. The
median observation time for overall survival was 78 months
for patients still alive at the time of analysis (range 3–
162 months). Fourteen patients (16.9%) died during follow-
up, and 31 patients (37.3%) experienced disease progression,
defined by either metastatic disease or local recurrence.
The selection of cases for this study was based on
availability of tissues. Patients with systemic disease (pM1)
at the time of diagnosis were excluded. Histological typing
of tumors was carried out according to the criteria of the
World Health Organization. Tumor stage was determined
according to the guidelines of the UICC [14]. Tumors were
graded according to Bloom and Richardson in the modifi-
cation of Elston and Ellis [3]. Data regarding the estrogen
receptor (ER) status, the expression of Her-2/neu (c-erbB2),
and the proliferative fraction (Mib-1) were gathered from
the archival pathology reports. The clinicopathological data
of the cases are described in Table 1.
Immunohistochemistry
Immunohistochemistry (IHC) staining was performed using
formalin-fixed, paraffin-embedded archival tissues. After
sectioning, tissue sections were applied to slides, deparaf-
finized with xylene, and gradually rehydrated. Antigen
retrieval was performed using a microwave oven (10 min at
250 W). The primary antibody anti-KPNA2 (goat polyclonal
SC6917, Santa Cruz Biotechnology; dilution 1:200) was
incubated at room temperature for 1 h. Detection was carried
out using an avidin–biotin peroxidase method with 3,3′-
diaminobenzidine as chromogen (ChemMate detection kit,
DAKO, Glostrup, Denmark). Brief nuclear counterstaining
with hematoxylin completed the procedure.
While normal testicular tissue served as a positive control
for KPNA2 IHC, unspecific binding of the secondary
antibody was excluded by omitting the primary antibody.
Evaluation
Evaluation of the immunohistochemical stainings was
independently carried out by two pathologists who were
Table 1 Clinicopathological characteristics of primary breast carci-
nomas
Variable No. (%)
Patient age
<60 years 47 (56.6)
≥60 years 36 (43.4)
pT status
pT1 51 (61.4)
pT2 24 (28.9)
pT3 6 (7.2)
pT4 2 (2.4)
pN status
pN0 34 (41.0)
pN1 21 (25.3)
pN2 14 (16.9)
pN3 13 (15.7)
Histological grade
G1 19 (22.9)
G2 40 (48.2)
G3 24 (28.9)
Histology
Ductal 78 (94)
Lobular 5 (6)
Estrogen receptor
Negative 19 (22.9)
Positive 55 (66.3)
Unknown 9 (10.8)
HER2 expression
0/1+ 45 (54.2)
2+/3+ 19 (22.9)
Unknown 19 (22.9)
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unaware of the outcome of the disease. Areas of invasive
carcinoma, DCIS, and adjacent histologically benign breast
tissue were considered separately. KNPA2 positivity was
defined as strong nuclear staining in at least 10% of cells.
Statistical analysis
Data were analyzed using the software package SPSS,
version 13.0. Spearman’s rank correlation was calculated,
and Fisher’s exact test and χ2 test were applied to evaluate
the statistical significance of association between expres-
sion of KPNA2 and clinicopathological variables.
For univariate survival analysis, cumulative survival
curves were calculated according to the Kaplan–Meier
method. Differences in survival were assessed with the log-
rank test. The impact of KPNA2 positivity, patient age,
histologic tumor type, pT status, pN status, tumor grade, ER
status, and cerbB2 status on overall survival time and
disease-free survival time was analyzed.
Results
KPNA2 immunostaining showed a predominantly nuclear
staining pattern, restricted to epithelial cells of normal breast
glands, DCIS, and invasive breast cancer (Fig. 1). Addition-
ally, a weak-to-moderate cytoplasmic staining was seen in
some cases, but was not subjected to further analysis.
Connective tissue cells, blood vessels, and inflammatory
cells did not display KPNA2 immunoreactivity.
KPNA2 immunostaining in normal breast tissue
Normal breast tissue adjacent to tumor was present and
evaluable in 78 (94%) patients. Nuclear staining was only
seen in ten (12.0%) samples. As the stained nuclei never
exceeded 1%, all samples were considered KPNA2 negative.
KPNA2 immunostaining in intraductal carcinoma
Seventy-five (90.4%) invasive breast cancer specimens
contained peritumoral DCIS, of which 40 cases (53.3%)
were of non-high grade and 35 (46.7%) were of high grade.
Staining of KPNA2 in at least 10% of nuclei was detected
in 16 samples (21.3%), whereas 59 samples (78.7%) were
KPNA2 negative. High-grade DCIS displayed KPNA2
staining in at least 10% of nuclei significantly more
frequently (n=12, 34.3%) than non-high-grade DCIS (n=
4, 10.0%; p=0.013). According to this, 23 samples of high-
grade DCIS (65.7%) and 36 samples of non-high-grade
DCIS (90.0%) were KPNA2 negative. KPNA2 immunore-
activity in DCIS correlated with KPNA2 expression in
adjacent invasive carcinomas (cc=0.725; p<0.001).
KPNA2 immunostaining in invasive breast carcinomas
KPNA2-positive immunostaining was seen in 26 (31.3%)
invasive carcinomas, the median percentage of positive
nuclei being 15%, with a maximum of 40%. KPNA2
positivity of invasive carcinoma revealed a statistically
significant correlation with higher pT status, nodal status,
histological grade, and a negative ER status (Table 2).
KPNA2 immunoreactivity in invasive carcinomas
and univariate survival analysis
Patients with KPNA2-positive breast carcinomas (≥10%)
had an estimated mean disease-free survival time of
69 months (95% confidence interval, 47–92 months)
Fig. 1 Hematoxylin and eosin staining and KPNA2 immunohisto-
chemistry. a Normal glandular breast tissue (HE). b Normal glandular
breast tissue displaying luminal epithelium with only single KPNA2-
positive nucleus and weak-to-moderate cytoplasmic staining. c Non-
high-grade DCIS (HE). d Few KPNA2-positive nuclei and weak
cytoplasmic staining in non-high-grade DCIS. e High-grade DCIS
(HE). f High-grade DCIS with markedly increased nuclear KPNA2
staining. g Invasive ductal carcinoma (HE). h Strong nuclear KPNA2
staining and moderate cytoplasmic staining in invasive ductal
carcinoma. a–h Original magnification ×200
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compared to 118 months (95% confidence interval, 100–
135 months) in patients with negative KPNA2 staining
(<10%; p=0.007; Fig. 2). For overall survival, no signifi-
cant differences were noted (data not shown).
Discussion
Nucleocytoplasmic transport mechanisms have been the target
of numerous studies for they are involved in many cellular
processes, such as gene expression, cell-cycle progression,
and signal transduction [1]. Regulating the subcellular
distribution of macromolecules, nuclear transport mecha-
nisms may also control their functions. There is increasing
evidence that these mechanisms may contribute to malignant
cell transformation, which makes their elements interesting
targets for further evaluation [11]. One of these elements is
KPNA2, an adaptor protein, which mediates the nuclear
import of macromolecules with a classical nuclear localiza-
tion signal. Linking a cargoprotein and Karyopherin beta,
KPNA2 initiates the transport through the nuclear core
complex. Thakur et al. [18] demonstrated that one of the
proteins whose subcellular distribution may be influenced by
KPNA2 is BRCA1, thereby connecting KPNA2 expression
with breast carcinogenesis.
Another cargoprotein of KPNA is TP53. Kim et al. [5]
identified a truncated form of KPNA in a breast cancer cell
line and showed that overexpression of this truncated form
results in cytoplasmic accumulation of TP53, whereas
overexpression of intact KPNA leads to a transactivation
of TP53-responsive genes in the nucleus.
Several gene expression profiling studies reported over-
expression of KPNA2 in breast cancer [2, 15, 19]. Sotiriou
et al. [15] found an association of KPNA2 overexpression
with higher histologic tumor grade, which matches our
findings on protein level. Dahl et al. were the first to
evaluate KPNA2 protein expression in breast cancer and
observed a strong nuclear immunohistochemical staining in
breast cancer cells compared to a weak or absent staining in
normal breast tissues. They also demonstrated an indepen-
dent negative association between KPNA2 expression in
the primary tumor and overall survival in breast cancer
patients which was particularly valid in the group of node-
positive cases. Importantly, KPNA2 expression appears to
be characteristic of the basal-like subtype of breast cancers,
which has an immediate impact on adjuvant therapy
planning [2].
The present study confirms our former results in an
independent and well-characterized breast cancer cohort,
using the cutoff value applied by Dahl et al. [2]. KPNA2
expression in at least 10% of nuclei was seen in 31% of
invasive carcinomas, whereas none of the matched normal
tissues was KPNA2 positive. Nuclear KPNA2 staining was
significantly correlated with higher tumor stage, lymph
node status, higher tumor grade, and negative ER status.
Consistent with the results reported by Dahl et al., survival
analysis revealed that patients with KPNA2-positive breast
carcinomas had significantly shorter disease-free survival
times, which clearly validates the prognostic value of
KPNA2 in breast cancer.
Further investigation of KPNA2 expression in preinva-
sive lesions of the breast appears mandatory to establish the
time point of KPNA2 upregulation in the multistep process
of mammary carcinogenesis. To our knowledge, the present
study includes the first description of KPNA2 protein
expression in matched DCIS and invasive lesions of the
breast. Staining of KPNA2 in at least 10% of nuclei was
detected in 21% of patients with DCIS. KPNA2 immuno-
reactivity in DCIS and invasive carcinomas correlated
significantly. The portion of KPNA2-positive cases in-
creased successively, comparing adjacent benign tissues
(0%), DCIS (21.3%), and invasive carcinomas (31%). This
indicates, that upregulation of KPNA2 may be an early
Table 2 Correlation of KPNA2 immunoreactivity in invasive breast
cancer with conventional clinical or tumor parameters
KPNA2 DCIS pT
status
pN
status
Grading ER
status
HER2
Correlation
coefficient
0.725 0.321 0.390 0.470 −0.316 0.148
Significance
(two-sided)
0.000 0.003 0.000 0.000 0.006 0.244
N 75 83 82 83 74 64
Fig. 2 Survival analysis. Kaplan–Meyer curves regarding disease-free
survival of patients with KPNA2 expression in less than 10% of nuclei
(dashed line) vs patients with KPNA2 expression in at least 10% of
nuclei in invasive carcinomas (bold line)
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event in carcinogenesis, which is also assumed by Klein
et al. [6], who found KPNA2 upregulated early in a mouse
model of breast cancer. This hypothesis is corroborated by
the fact that samples showing positive KPNA2 staining in
at least 10% of nuclei were significantly less frequent in the
group of low-grade DCIS (10%) compared to those cases
displaying adjacent high-grade DCIS (34.3%). The portion
of KPNA2-positive cases in the latter group was almost
equivalent to the portion of KPNA2-positive invasive
carcinomas, which suggests that KPNA2 overexpression is
preceding invasion. Clearly, further studies are needed to
clarify the functional role of KPNA2 in breast carcinogenesis.
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